Effectiveness of targeted therapy after immunotherapy in metastatic kidney cancer patients

In this retrospective international study, the effectiveness of targeted therapy following discontinuation of immunotherapy for patients with metastatic renal cell carcinoma (RCC) in the real world was investigated. There were 314 patients in the study; 276 (87.9%) were treated with vascular endothelial growth factor receptor tyrosine kinase inhibitors (VEGFR-TKIs), such as sunitinib, axitinib and cabozantinib, […]

read more

Real world use of targeted therapies in war veterans with kidney cancer

A retrospective study of the use of targeted therapies for advanced renal cell carcinoma (RCC) in war veterans in the USA reported poorer overall survival outcomes than those from clinical trials, as well as shorter treatment durations for first-line therapies with more frequent adverse events, dose reductions, and drug discontinuations. The study was published in […]

read more

Panobinostat plus everolimus not effective in metastatic kidney cancer

A recent phase I clinical trial assessed the combination of everolimus (an mTOR inhibitor) with panobinostat (a histone deacetylase inhibitor) in 21 patients with clear-cell metastatic renal cell carcinoma (RCC) who had disease progression within 6 months of stopping treatment with VEGFR TKIs. Median progression-free survival was 4.1 months. Anaemia and thrombocytopenia were the most […]

read more

The effect of antibiotic use on outcomes with kidney cancer drug treatments

A recent study has looked at the use of antibiotics with systemic drug treatments for renal cell carcinoma (RCC). The study investigated patients taking immune checkpoint inhibitors (146 patients), interferon-α (510 patients), mTOR inhibitors (660 patients) and VEGF targeted therapies (2,974 patients). The latter three groups were on phase II/III clinical trials, while the immunotherapy […]

read more

Effect of antibiotic use on outcomes with systemic therapies in metastatic kidney cancer

This study, published in European Urology Oncology this week, investigated the impact of antibiotic use on clinical outcomes in patients with metastatic renal cell carcinoma (RCC) treated with systemic anti-cancer drugs. The use of antibiotics alters the microbes living in our guts (gut microbiota), which is a key regulator of immune system. In the study, […]

read more

Long term survival of patients with metastatic kidney cancer – a real world study

This real world study reports on the long term survival of patients with metastatic renal cell carcinoma (RCC) who have taken 1 to 4 lines of systemic drug treatment sequentially under real life conditions. Patients were treated according to their prognostic score (good, intermediate, poor). Overall survival was 57 months in patients with good or intermediate […]

read more

Current role of mTOR inhibitors in metastatic kidney cancer

The following video interview with Dr Eric Jonasch, from the MD Anderson Cancer Center, Houston, Texas, describes the current role of mTOR inhibitors for the treatment of metastatic renal cell carcinoma (mRCC). Watch the video interview on Practice Update here

read more

MD Anderson Cancer Center 13th Update on the Management of Genitourinary Malignancies Conference

The MD Anderson Cancer Center (MDACC) 13th Update on the Management of Genitourinary Malignancies Conference took place in Houston, Texas at the end of last week (9-10 November). Kidney cancer highlights from the meeting have been published by UroToday. You can read more online on UroToday below: MDACC 2018: Promising Emerging Systemic Therapies for mRCC MDACC […]

read more

What the future may hold for the treatment of renal cell carcinoma

The following article from OncLive discusses the rapidly changing landscape in the treatment of renal cell carcinoma (RCC) and what the future may hold: The Rapidly Changing Landscape in RCC Therapy: What Future Research May Hold

read more

Adjuvant therapy for renal cell carcinoma

The following articles from various urology conferences in 2018 summarise the status of research with respect to adjuvant therapy after nephrectomy for people with localised renal cell carcinoma (RCC). Many adjuvant therapies have been assessed in clinical trials, such as radiotherapy, vaccines, immunotherapy, vascular endothelial growth factor (VEGF) tyrosine kinase inhibitors (TKI), and checkpoint inhibitors. […]

read more
Showing 1 to 10 of 14 results
  TOP